Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?

Fig. 2

Clinical application of CRISPR for the treatment of T1D MSCs are isolated from a variety of adult tissue sources including bone marrow, adipose tissue, and dental pulp for ex vivo culture. MSCs are subsequently gene modified with the nuclease-deficient dCas9-transcriptional activator CRISPR complex and specific sgRNA for the desired purpose of either generating enhanced MSCs that maintain their immunomodulatory properties as an immunotherapy, or for the generation of IPCs. The generated therapy is subsequently administered to a trial participant either systemically (immunotherapy) or subcutaneously (IPCs) in an area conducive to vascularisation of the transplanted IPCs. CRISPR clustered regularly interspaced short palindromic repeat, MSC mesenchymal stem cell, IPC insulin-producing cell

Back to article page